A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 Versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment In Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer. (FLAURA Study)

Project: Research

Project Details

Project Description

SERP Reference Number: HREC/14/SHA/68
Monash Health HREC Ref: 14409A
Effective start/end date26/02/1925/02/24


  • clinical trial
  • phase 3 study
  • lung cancer